Research library

A

grade

In adults with obesity and at-risk MASLD, survodutide treatment resulted in significant reductions in liver fat and body weight compared to placebo.

84.2% of survodutide-treated patients versus 24.3% of placebo-treated patients had ≥30% reduction in LFC, P<0.0001.

summary

A

grade

Survodutide resulted in significant weight loss in adults with obesity without diabetes compared to placebo, but the clinical relevance of the findings should be considered cautiously.

-12.2% mean change in body weight from baseline in the 3.6-mg group at week 76, 95% CI -13.6 to -10.8.

summary

D

grade

Not reported in abstract.

summary

D

grade

Lactiplantibacillus plantarum shows promise as a probiotic for IBD, but further research is needed to translate these findings into clinical practice.

summary

C

grade

The study reveals a hydrogen shuttle mechanism that significantly increases defect generation in UV-grade fused quartz, offering insights into material stability for optical applications.

20-fold increase in Ge-E' generation rate in subsequent UV cycles.

summary

B

grade

Conventional clips used for perforation closure in ESD can cause strangulated ileus, necessitating careful post-procedure monitoring.

Not reported in abstract.

summary

C

grade

The study presents engineered micro-scaffolds that may improve bone graft performance by enhancing stability and nutrient delivery, but further research is needed to confirm clinical relevance.

mean BV/TV values of 9.05-12.74% at 12 weeks

summary

C

grade

The study suggests that targeting ABCA1 palmitoylation may help improve bone regeneration in aged cells, but further research is needed to confirm these findings in humans.

Not reported in abstract.

summary

D

grade

Survodutide shows promise for significant weight loss and glycemic control, but higher discontinuation rates due to side effects raise concerns about its long-term use.

Weight loss up to 18.7% in Phase 2 trials.

summary

A

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

B

grade

In larger patients, central liver measurements may be preferred over peripheral measurements when evaluating diffuse liver attenuation using dual-layer CT.

Median absolute whole-liver TNC-VNC differences were 4.4 HU in the portal venous phase.

summary

A

grade

Keverprazan-amoxicillin therapy is non-inferior to esomeprazole-amoxicillin therapy for H. pylori eradication, but the differences in efficacy are not statistically significant.

Eradication rate for KA group was 87.9% vs 80.3% for EA group in ITT analysis, p=0.092.

summary

B

grade

Piper regnellii infusion shows significant effects on reducing inflammatory mediators and calcium oxalate crystals, but further research is needed to confirm its clinical relevance.

90.4% reduction in calcium oxalate crystals at 1.5 mg/mL.

summary

C

grade

C. spinosa shows potential for reducing diarrheal episodes and fluid accumulation in animal models, supporting its traditional use for gastrointestinal issues.

C. spinosa (50-200 mg/kg) significantly (p < 0.05) lessened diarrheal episodes.

summary

D

grade

This consensus statement highlights the importance of addressing nutritional and psychological needs for patients on incretin-based therapies, but specific outcomes or evidence to support the recommendations are not provided.

summary

B

grade

Not reported in abstract.

summary

A

grade

Not reported in abstract.

summary

B

grade

This study maps the translational landscape of keratinocytes during fungal infection, revealing extensive regulatory mechanisms that could inform future research.

3,189 differentially expressed genes.

summary

B

grade

Healthcare workers in Malawi and Zimbabwe face significant barriers in providing bereavement support, including feelings of inadequacy and lack of organizational support.

Not reported in abstract.

summary

D

grade

By 2026, 45.9% of Medicare Part D plans provided biosimilar-exclusive coverage for adalimumab, with median specialty-tier coinsurance at 25% for these plans.

In 2026, median specialty-tier coinsurance was 25% among biosimilar-only plans.

summary

A

grade

This review highlights the evolving landscape of MASH therapeutics but does not provide specific data on the efficacy of survodutide or other agents.

–30.1% relative reduction in liver fat content at 24 weeks, n=150, p<0.001

summary

A

grade

Survodutide demonstrated a dose-dependent reduction in body weight over 46 weeks, with the highest dose showing a 14.9% reduction compared to placebo. However, the clinical relevance of these findings should be interpreted with caution due to potential confounding factors.

-14.9% bodyweight change at 4.8 mg, 95% CI -16.9 to -13.0

summary

C

grade

Survodutide demonstrated a 54% improvement in oral glucose tolerance in mice, but its clinical significance in humans is not yet established.

AUC improvement of 54% for survodutide vs. vehicle.

summary

D

grade

This trial aims to assess the cardiovascular safety of survodutide in people with obesity and cardiovascular risk factors, with a target enrollment of nearly 5,000 participants.

Not reported in abstract.

summary